Patient recruitment starts for the international PRO-SID study evaluating Panzyga® for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary immunodeficiency
Octapharma is pleased to announce that the first site for the international PRO-SID (Primary Infection Prophylaxis with Panzyga® in Secondary Immunodeficiency in Chronic Lymphocytic Leukaemia) study w…
뉴스와이어공모
